Clinical Approach to Progressive Supranuclear Palsy.
- Author:
Helen LING
1
Author Information
- Publication Type:Review
- Keywords: Progressive supranuclear palsy; Richardson's syndrome; Corticobasal syndrome; Tauopathy; Atypical parkinsonism
- MeSH: Atrophy; Biomarkers; Cerebrospinal Fluid; Magnetic Resonance Imaging; Mesencephalon; Neurons; Pathology; Phenotype; Population Characteristics; Positron-Emission Tomography; Steel; Supranuclear Palsy, Progressive*; Tauopathies
- From:Journal of Movement Disorders 2016;9(1):3-13
- CountryRepublic of Korea
- Language:English
- Abstract: Sixty years ago, Steele, Richardson and Olszewski designated progressive supranuclear palsy (PSP) as a new clinicopathological entity in their seminal paper. Since then, in addition to the classic Richardson's syndrome (RS), different clinical phenotypic presentations have been linked with this four-repeat tauopathy. The clinical heterogeneity is associated with variability of regional distribution and severity of abnormal tau accumulation and neuronal loss. In PSP subtypes, the presence of certain clinical pointers may be useful for antemortem prediction of the underlying PSP-tau pathology. Midbrain atrophy on conventional MRI correlates with the clinical phenotype of RS but is not predictive of PSP pathology. Cerebrospinal fluid biomarkers and tau ligand positron emission tomography are promising biomarkers of PSP. A multidisciplinary approach to meet the patients' complex needs is the current core treatment strategy for this devastating disorder.
